Physician profile
Ignacio L Gallardo
NPI 1407896913
$1,984.70
in general payments reported to CMS, 2019-2025
21 companies · $73.80 in 2025
The $73.80 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $538 · 2021: $467 · 2022: $159 · 2023: $72.73 · 2024: $112 · 2025: $73.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $258.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $403.48 | 2019-2024 | Lifevest |
| Biotronik INC. | $262.85 | 2019-2022 | |
| Astellas Pharma US INC | $244.62 | 2019-2021 | |
| Abbott Laboratories | $209.38 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $183.92 | 2019-2024 | |
| Medtronic, INC. | $117.85 | 2021-2023 | Micra |
| Merck Sharp & Dohme LLC | $94.76 | 2021-2025 | Verquvo |
| Pfizer INC. | $75.45 | 2019 | |
| Medtronic Vascular, INC. | $68.89 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $56.37 | 2019-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $46.83 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.22 | 2021-2024 | Jardiance |
| Amarin Pharma, INC. | $34.65 | 2019-2021 | |
| Elutia, INC. | $28.29 | 2021-2022 | |
| Abiomed | $24.03 | 2024 | Impella |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $17.84 | 2025 | Amvuttra |
| Amgen INC. | $17.82 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.53 | 2021 | |
| Novo Nordisk INC | $14.39 | 2024 | Wegovy |
| Sanofi-Aventis U.S. LLC | $14.07 | 2019 | |
| Irhythm Technologies, INC. | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ignacio Gallardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.